Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-31
2011-05-31
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C424S009200
Reexamination Certificate
active
07951778
ABSTRACT:
The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to sarcoidosis. The peptides which can be used according to the invention for the treatment of said disease comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of sarcoidosis. Furthermore, the present invention discloses a method for the treatment patients suffering from sarcoidosis.
REFERENCES:
patent: 3880826 (1975-04-01), Said et al.
patent: 3898329 (1975-08-01), Said et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4237046 (1980-12-01), Bodanszky
patent: 0184309 (1986-06-01), None
patent: 0225020 (1987-06-01), None
patent: 0325044 (1989-07-01), None
patent: 0204447 (1991-10-01), None
patent: 0405242 (1991-10-01), None
patent: 0463450 (1994-02-01), None
patent: 0613904 (1994-09-01), None
patent: 0620008 (1994-09-01), None
patent: 0536741 (1995-04-01), None
patent: 0663406 (1995-07-01), None
patent: 0401384 (1996-03-01), None
patent: WO-8905857 (1989-06-01), None
patent: WO-9106565 (1995-01-01), None
patent: WO-9527496 (1995-10-01), None
patent: WO-9729126 (1997-08-01), None
patent: WO-9735561 (1997-10-01), None
patent: WO-01/34088 (2001-05-01), None
patent: WO-0116295 (2001-08-01), None
patent: WO 02/43746 (2002-06-01), None
patent: WO-0243746 (2002-06-01), None
Rudinger J, “Characteristics of the amino acids as components of a peptide hormone sequence,” Peptide Hormones, Edited by JA Parsons, University Park Press, Jun. 1976, pp. 1-7.
“Designing Custom Peptides” from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Schinzel R, Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” FEBS, Jul. 1991, 286(1,2): 125-128.
Berendsen HJC, “A Glimpse of the Holy Grail?” Science, Oct. 1998, 282: 642-643.
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Ngo JT, Marks J, Karplus M, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495.
Bradley CM, Barrick D, “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol., 2002, 324: 373-386.
Sarcoidosis from Merck manual, pp. 1-6. Accessed Sep. 21, 2009.
Francis, Gillian E., “Protein modification and fusion proteins”, Focus on Growth Factors, vol. 3, No. 2, May 1992, (pp. 4-10).
Remington's Pharmaceutical Sciences 18th edition (1990), Mack Publishing Company, Chapter 75, Alfonso R. Gennaro, Editor and Chairman, (pp. 1435-1450).
Remington's Pharmaceutical Sciences 18th edition (1990), Mack Publishing Company, Chapter 83, Alfonso R. Gennaro, Editor and Chairman, (pp. 1519-1544).
Remington's Pharmaceutical Sciences 18th edition (1990), Mack Publishing Company, Chapter 88, Alfonso R. Gennaro, Editor and Chairman, (pp. 1615-1632).
Remington's Pharmaceutical Sciences 18th edition (1990), Mack Publishing Company, Chapter 89, Alfonso R. Gennaro, Editor and Chairman, (pp. 1633-1665).
Remington's Pharmaceutical Sciences 18th edition (1990), Mack Publishing Company, Chapter 92, Alfonso R. Gennaro, Editor and Chairman, (pp. 1694-1712).
Keith I.M. Physiological Research, vol. 49(5), 2000, pp. 519-537 “The role of endogenous lung neuropeptides in regulation of the pulmonary circulation”.
Pavlou T. A. et al., “Infusion of Vasoactive Intestinal Peptide Improves Hemodynamics in Primary Pulmonary Hypertension”, American Review of Respiratory Disease, vol. 14, 1993, p. A536 Suppl. S.
Iwanga et al., “Vasoactive Intestinal Peptide VIP Protects Against Acid-Induced Acute Lung Injury in Isolated Perfused Rat Lungs,” 1989 Japanese Journal of Thoracic Diseases vol. 27(7) pp. 789-795 (Abstract only).
Maruno et al., “VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells,” 1995 American Journal of Physiology vol. 268(6) pp. L1047-L1051.
Kawasaki et al., “The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery,” 1997 British Journal of Pharmacology Vo. 121(5) pp. 977-985.
Platoshyn et al., “Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation” Nov. 1, 2000 American Journal of Physiology vol. 279(5) pp. C1540-C1549.
Hultgardh et al.; “Growth-inhibitory properties of vasoactive intestinal polypeptides.”; Regul. Pept.; p. 267-274; 1998.
Ishihara et al.; “Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.”; Nueron 8; p. 811-819; 1992.
Mood et al.; Proceedings of the National Academy of Science, USA, 90; p. 4345; 1992.
Wollman et al.; Brain Research 624; p. 339; 1993.
Said, S. I.; “Vasoactive intestinal polypeptide (VIP) in asthma.”; Annals New York Academy of Science, 629; p. 305-318; 1991.
Hamasaki et al.; “Relaxant action of VIP on cat pulmonary artery: comparison with acetylcoholine, isoproterenol, and PGE1.”; Journal of Applied Physiology, 54; p. 1607-1611; 1982.
Iwabuchi et al.; “Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung.”; Respiration, 64; p. 54-58; 1997.
Saga et al.; “Vasoactive intestinal peptide relaxes strips of human bronchus, pulmonary artery, and lung parenchyma.”; Trans Association of American Physicians, 97; p. 304-310; 1984.
Raderer et al. “1231-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.”; British Journal of Cancer, 78; p. 1-5; 1998.
Raderer et al.; “Iodine-123-vasoactive intestinal receptor scanning in patients with pancreatic cancer.”; Journal of Nuclear Medicine, 39; p. 1570-1575; 1998.
Raderer et al.; “Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111) In-DTPA-D-Phel-octreotide in 194 carcinoid patients.”; Vienna University Experience 1993-1998; Journal of Clinical Oncology, 18; p. 1331-1336; 2000.
Virgolini et al.; “Vasoactive intestinal peptide receptor scintography.”; Journal of Nuclear Medicine, 36; p. 1732-1739; 1995.
Sada et al.; Journal of Fermentation Bioengineering, 71; p. 137-139; 1999.
Newman et al.; “Sacroidosis”; New England Journal of Medicine, 336; p. 1224-1234; 1997.
Chesnutt, A. N.; “Enigmas in Sarcoidosis”; Western Journal of Medicine, 162; p. 519-526; 1995.
Rakel, R. E.; “Conn's current thearapy 1995: latest approved methods of treatment for the practicing physician.”; Philadelphia: Saunders 1995; p. 195-199.
Crystal et al.; “Interstitial lung diseases of unkown cause. Disorders characterized by chronic inflamation of the lower respiratory tract (first of two parts)”; New England Journal of Medicine, 310; p. 154-166; 1984.
Staton et al.; “Chronic diffuse infiltrative lung disease”; Scientific American; p. 11-24; 1997.
Winterbauer et al.; “Use of pulmonary function tests in the management of sarcoidosis.”; Chest Journal, 78; p. 640-647; 1980.
Muther et al.; “Renal manifestations of sarcoidosis.”; Archive of Internal Medicine, 141; p. 643-645; 1981.
DeRemee; “Sarcoidosis”; Mayo Clinic Proceedings, 70; p. 177-181; 1995.
Sharma et al.; “Myocardial Sarcoidosis”; Chest
Ha Julie
mondoBIOTECH AG
Winstead PC
LandOfFree
Use of compounds having the biological activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of compounds having the biological activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of compounds having the biological activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662436